SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Autres langues Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Actions

600196

CNE000000X38

Cours en clôture Shanghai S.E. Autres places de cotation 00:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
23,19 ^CNY	+1,35%		+3,02%	-7,35%

24/04	Une unité de Fosun Pharma obtient l'autorisation de mise sur le marché d'un médicament contre la tuberculose de la part d'un organisme de réglementation chinois	MT
08/04	La Chine accepte les demandes de nouveaux médicaments pour les médicaments de Fosun Pharma contre le syndrome de surcharge en fer	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator	24/04
China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy	18/04
Fosun Pharma Unit’s New Drug Application for CMV, HSV Drug Accepted by Chinese Regulator	17/04
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	15/04
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs	08/04
Tranche Update on Shanghai Fosun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.	03/04
Telefield Medical Imaging Limited announced that it has received HKD 59.571525 million in funding Gobi Partners	31/03
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates	27/03
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	27/03
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023	26/03
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	26/03
Shanghai Fosun Pharma Unit's Oral Schizophrenia Drug Gets Marketing Registration	14/03
Fosun Pharma Unit Gets China OK for Phase I Trial for Solid Tumor Drug	08/03
Fosun Pharma Unit to Start First Phase of Trial of Cancer Drug Candidate	08/03
Fosun Pharma Chairman Proposes Buyback of Up to 200 Million Yuan	04/03
Fosun Pharma Subsidiaries Get Nod to Trial Leukemia Drugs	01/03
Registration Application of Hypokalemia Drug by Shanghai Fosun Pharmaceutical Unit Accepted by Chinese Regulator	20/02
Yuyuan Tourist Mart CFO Steps Down	05/02
Shanghai Fosun Unit Gets Clearance For China Phase II Trial of Amyloidosis Drug	25/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Actions

600196

CNE000000X38

Autres langues

Filtres